Contents

List of contributors, xvii
Preface, xxi

Section 1  An introduction to the human tissue microbiome, 1

1 The human microbiota: an historical perspective, 3
   Michael Wilson
   1.1 Introduction: the discovery of the human microbiota: why do we care?, 3
   1.2 The importance of the indigenous microbiota in health and disease, 3
     1.2.1 The indigenous microbiota and human disease, 4
     1.2.2 The indigenous microbiota and human health, 4
   1.3 The development of technologies for characterising the indigenous microbiota, 8
     1.3.1 Light microscopy, 9
     1.3.2 Electron microscopy, 11
     1.3.3 Culture-based approaches to microbial community analysis, 12
   1.4 Culture-independent approaches to microbial community analysis, 29
   1.5 Determination of microbial community functions, 31
   1.6 Closing remarks, 32
   Take-home message, 32
   References, 33

2 An introduction to microbial dysbiosis, 37
   Mike Curtis
   2.1 Definition of dysbiosis, 37
   2.2 The ‘normal’ microbiota, 38
   2.3 Main features of dysbiosis, 45
   2.4 Conclusions, 49
   Take-home message, 53
   Acknowledgment, 53
   References, 53

3 The gut microbiota: an integrated interactive system, 55
   Hervé M. Blottière and Joël Doré
   3.1 Introduction, 55
   3.2 Who is there, how is it composed?, 56
   3.3 A system in interaction with food, 58
   3.4 A system highly impacted by the host, 61
   3.5 A system in interaction with human cells, 62
   3.6 Conclusion: an intriguing integrated interactive system
deserving further study, 63
   Take-home message, 63
   References, 63
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>The oral microbiota, 67</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td><em>William G. Wade</em></td>
<td></td>
</tr>
<tr>
<td>4.1</td>
<td>Introduction, 67</td>
<td></td>
</tr>
<tr>
<td>4.2</td>
<td>Composition of the oral microbiome, 68</td>
<td></td>
</tr>
<tr>
<td>4.2.1</td>
<td>Archaea, 68</td>
<td></td>
</tr>
<tr>
<td>4.2.2</td>
<td>Fungi, 68</td>
<td></td>
</tr>
<tr>
<td>4.2.3</td>
<td>Protozoa, 68</td>
<td></td>
</tr>
<tr>
<td>4.2.4</td>
<td>Viruses, 69</td>
<td></td>
</tr>
<tr>
<td>4.2.5</td>
<td>Bacteria, 69</td>
<td></td>
</tr>
<tr>
<td>4.3</td>
<td>The oral microbiota in health, 71</td>
<td></td>
</tr>
<tr>
<td>4.3.1</td>
<td>Evolution of the oral microbiota, 71</td>
<td></td>
</tr>
<tr>
<td>4.3.2</td>
<td>Role of oral bacteria in health, 72</td>
<td></td>
</tr>
<tr>
<td>4.4</td>
<td>Role of oral microbiome in disease, 73</td>
<td></td>
</tr>
<tr>
<td>4.4.1</td>
<td>Dental caries, 73</td>
<td></td>
</tr>
<tr>
<td>4.4.2</td>
<td>Gingivitis, 74</td>
<td></td>
</tr>
<tr>
<td>4.4.3</td>
<td>Oral bacteria and non-oral disease, 74</td>
<td></td>
</tr>
<tr>
<td>4.5</td>
<td>Future outlook, 75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Take-home message, 75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>References, 76</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>The skin microbiota, 81</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td><em>Patrick L.J.M. Zeeuwen and Joost Schalkwijk</em></td>
<td></td>
</tr>
<tr>
<td>5.1</td>
<td>Normal skin, 81</td>
<td></td>
</tr>
<tr>
<td>5.2</td>
<td>Skin diseases, 83</td>
<td></td>
</tr>
<tr>
<td>5.2.1</td>
<td>Atopic dermatitis, 83</td>
<td></td>
</tr>
<tr>
<td>5.2.2</td>
<td>Psoriasis, 84</td>
<td></td>
</tr>
<tr>
<td>5.2.3</td>
<td>Acne, 85</td>
<td></td>
</tr>
<tr>
<td>5.2.4</td>
<td>Rosacea, 85</td>
<td></td>
</tr>
<tr>
<td>5.2.5</td>
<td>Seborrheic dermatitis and dandruff, 86</td>
<td></td>
</tr>
<tr>
<td>5.2.6</td>
<td>Primary immunodeficiencies, 86</td>
<td></td>
</tr>
<tr>
<td>5.3</td>
<td>Experimental studies, 87</td>
<td></td>
</tr>
<tr>
<td>5.4</td>
<td>Dynamics of the skin microbiome, 87</td>
<td></td>
</tr>
<tr>
<td>5.5</td>
<td>Axillary skin microbiome transplantation, 89</td>
<td></td>
</tr>
<tr>
<td>5.6</td>
<td>Mouse skin microbiome studies, 89</td>
<td></td>
</tr>
<tr>
<td>5.7</td>
<td>Concluding remarks, 90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Take-home message, 90</td>
<td></td>
</tr>
<tr>
<td></td>
<td>References, 90</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Metagenomic analysis of the human microbiome, 95</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td><em>Luis G. Bermúdez-Humarán</em></td>
<td></td>
</tr>
<tr>
<td>6.1</td>
<td>Introduction, 95</td>
<td></td>
</tr>
<tr>
<td>6.2</td>
<td>The human microbiome, 96</td>
<td></td>
</tr>
<tr>
<td>6.3</td>
<td>Changes in microbiota composition during host life cycles, 97</td>
<td></td>
</tr>
<tr>
<td>6.4</td>
<td>The human microbiome and the environment, 98</td>
<td></td>
</tr>
<tr>
<td>6.5</td>
<td>Disease and health implications of microbiome, 99</td>
<td></td>
</tr>
<tr>
<td>6.5.1</td>
<td>The skin microbiota, 99</td>
<td></td>
</tr>
<tr>
<td>6.5.2</td>
<td>The airway microbiome, 99</td>
<td></td>
</tr>
<tr>
<td>6.5.3</td>
<td>Vaginal microbiome, 100</td>
<td></td>
</tr>
<tr>
<td>6.5.4</td>
<td>Gut microbiota and disease, 101</td>
<td></td>
</tr>
<tr>
<td>6.5.5</td>
<td>Metabolic disorders (obesity/diabetes), 103</td>
<td></td>
</tr>
</tbody>
</table>
6.6 Conclusions, 105
Take-home message, 105
References, 106

Section 2  Microbiota-microbiota and microbiota-host interactions in health and disease, 113

7  Systems biology of bacteria-host interactions, 115
Almut Heinken, Dmitry A. Ravcheev and Ines Thiele
7.1 Introduction, 115
7.2 Computational analysis of host-microbe interactions, 118
   7.2.1 Analysis of metagenomic data, 118
   7.2.2 Metabolic reconstruction through comparative genomics, 119
7.3 Network-based modeling, 121
   7.3.1 Topological network modeling, 121
   7.3.2 Constraint-based modeling, 123
   7.3.3 Metabolic reconstructions of human metabolism, 124
   7.3.4 Constraint-based modeling of host-microbe interactions, 124
7.4 Other computational modeling approaches, 127
   7.4.1 Ordinary differential equation (ODE) models, 127
   7.4.2 Kinetic modeling, 128
7.5 Conclusion, 129
Take-home message, 130
Acknowledgments, 130
References, 131

8  Bacterial biofilm formation and immune evasion mechanisms, 139
Jessica Snowden
8.1 Introduction, 139
8.2 Biofilms in human disease, 139
8.3 Biofilm formation, 141
8.4 Immune responses to biofilms, 143
   8.4.1 Innate immune responses, 144
   8.4.2 Adaptive immune responses, 146
   8.4.3 Fibroblasts, epithelial cells and other immune responses, 147
8.5 Biofilm immune evasion strategies, 147
8.6 Vaccines and biofilm therapeutics, 148
8.7 Conclusions, 149
Take-home message, 149
References, 150

9  Co-evolution of microbes and immunity and its consequences for modern-day life, 155
Markus B. Geuking
9.1 Introduction, 155
9.2 Symbiosis in eukaryotic evolution, 156
9.3 Evolution of the (innate and adaptive) immune system, 157
   9.3.1 Immune proteins, 157
   9.3.2 Evolution of adaptive immunity, 158
   9.3.3 Two separate adaptive immune systems evolved, 158
9.4 Hygiene hypothesis, 159
9.5 What drives the composition of the microbiota?, 160
9.6 The pace of evolution, 161
Take-home message, 162
References, 162

10 How viruses and bacteria have shaped the human genome: the implications for disease, 165
Frank Ryan
10.1 Genetic symbiosis, 165
10.2 Mitochondria: symbiogenesis in the human, 167
10.3 Viral symbiogenesis, 169
10.4 HERV proteins, 172
Take-home message, 174
References, 174

11 The microbiota as an epigenetic control mechanism, 179
Boris A. Shenderov
11.1 Introduction, 179
11.2 Background on epigenetics and epigenomic programming/reprogramming, 180
11.3 Epigenomics and link with energy metabolism, 184
11.4 The microbiota as a potential epigenetic modifier, 185
11.5 Epigenetic control of the host genes by pathogenic and opportunistic microorganisms, 188
11.6 Epigenetic control of the host genes by indigenous (probiotic) microorganisms, 189
11.7 Concluding remarks and future directions, 191
Take-home message, 193
References, 193

12 The emerging role of propionibacteria in human health and disease, 199
Holger Brüggemann
12.1 Introduction, 199
12.2 Microbiological features of propionibacteria, 199
12.3 Population structure of \textit{P. acnes}, 201
12.4 Propionibacteria as indigenous probiotics of the skin, 202
12.5 Propionibacteria as opportunistic pathogens, 203
12.6 Host interacting traits and factors of propionibacteria, 205
12.7 Host responses to \textit{P. acnes}, 206
   12.7.1 Innate immune responses, 206
   12.7.2 Adaptive immune responses, 207
   12.7.3 Host cell tropism of \textit{P. acnes}, 208
12.8 \textit{Propionibacterium}-specific bacteriophages, 208
12.9 Concluding remarks, 209
Take-home message, 210
References, 210
Section 3 Dysbioses and bacterial diseases: Metchnikoff’s legacy, 215

13 The periodontal diseases: microbial diseases or diseases of the host response?, 217

  Luigi Nibali
  13.1 The tooth: a potential breach in the mucosal barrier, 217
  13.2 The periodontium from health to disease, 217
  13.3 Periodontitis: one of the most common human diseases, 219
  13.4 Periodontal treatment: a non-specific biofilm disruption, 220
  13.5 Microbial etiology, 220
  13.6 The host response in periodontitis, 221
  13.7 Conclusions, 223
  Take-home message, 223
  References, 223

14 The polymicrobial synergy and dysbiosis model of periodontal disease pathogenesis, 227

  George Hajishengallis and Richard J. Lamont
  14.1 Introduction, 227
  14.2 A (very) polymicrobial etiology of periodontitis, 229
  14.3 Synergism among periodontal bacteria, 230
  14.4 Interactions between bacterial communities and epithelial cells, 232
  14.5 Manipulation of host immunity, 233
  14.6 Conclusions, 237
  Take-home message, 238
  References, 239

15 New paradigm in the relationship between periodontal disease and systemic diseases: effects of oral bacteria on the gut microbiota and metabolism, 243

  Kazuhisa Yamazaki
  15.1 Introduction, 243
  15.2 Association between periodontal and systemic diseases, 244
    15.2.1 Periodontal disease and diabetes, 244
    15.2.2 Periodontal disease and atherosclerotic vascular diseases, 245
    15.2.3 Periodontal disease and rheumatoid arthritis, 246
    15.2.4 Periodontal disease and non-alcoholic fatty liver disease, 246
    15.2.5 Periodontal disease and pre-term birth, 247
    15.2.6 Periodontal disease and obesity, 248
    15.2.7 Periodontal disease and cancer, 248
    15.2.8 Periodontal disease and inflammatory bowel disease, 249
  15.3 Issues in causal mechanisms of periodontal disease for systemic disease, 249
    15.3.1 Endotoxemia (bacteremia), 249
    15.3.2 Inflammatory mediators, 251
    15.3.3 Autoimmune response from molecular mimicry, 251
  15.4 New insights into the mechanisms linking periodontal disease and systemic disease, 252
  15.5 Effect of oral administration of P. gingivalis on metabolic change and gut microbiota, 252
16 The vaginal microbiota in health and disease, 263

S. Tariq Sadiq and Phillip Hay

16.1 What makes a healthy microbiota, 263
  16.1.1 How does the vaginal microbiota mediate healthiness?, 264
  16.1.2 Establishment of the vaginal microbiota, 264
  16.1.3 The role of host genetic variation on vaginal health, 264
  16.1.4 Impact of age, menstrual cycle and environmental factors on vaginal health, 265

16.2 The vaginal microbiota in disease, 265
  16.2.1 Bacterial vaginosis, 265
  16.2.2 Clinical consequences of altered vaginal microbiota (see Figure 1), 268
  16.2.3 Vaginal microbiota and transmission and susceptibility to HIV infection, 269

16.3 Conclusions, 269
  Take-home message, 269
  References, 270

Section 4 Dysbioses and chronic diseases: is there a connection?, 273

17 Reactive arthritis: the hidden bacterial connection, 275

John D. Carter

17.1 Introduction, 275
17.2 Reactive arthritis, 276
17.3 Pathophysiology of ReA, 277
17.4 Questions remain, 279
17.5 Conclusion, 280
  Take-home message, 280
  References, 280

18 Rheumatoid arthritis: the bacterial connection, 283

Jacqueline Detert

18.1 Preclinical rheumatoid arthritis, 283
18.2 Predisposition to RA, 284
18.3 MCH-HLA and genetic predisposition to RA, 284
18.4 Molecular mimicry in RA, 285
18.5 Innate immune system and RA, 285
18.6 Bystander activation and pattern recognition receptors, 286
18.7 Antibodies and neoepitopes, 287
18.8 Superantigens, 287
18.9 LPS, 287
18.10 Bacterial DNA and peptidoglycans, 288
18.11 Heat-shock proteins, 288
18.12 Toll-like and bacterial infections, 288
18.13 Proteus mirabilis, 288
18.14 Porphyromonas gingivalis and RA, 289
18.15 Gastrointestinal flora and RA, 290
18.16 Smoking, lung infection and RA, 291
18.17 Where to go from here?, 291
Take-home message, 291
References, 292

19 Inflammatory bowel disease and the gut microbiota, 301
  Nik Ding and Ailsa Hart
  19.1 The microbiota in inflammatory bowel disease, 301
  19.2 Dysbiosis and IBD pathogenesis, 301
  19.3 Environmental factors affecting microbiome composition, 302
    19.3.1 Diet, 302
    19.3.2 Age, 303
  19.4 Genetics and application to the immune system and dysbiosis in IBD, 303
  19.5 An overview of gut microbiota studies in IBD, 305
  19.6 Specific bacterial changes in IBD, 306
    19.6.1 Potentiators, 306
    19.6.2 Protectors, 307
    19.6.3 Anti-inflammatory effects of microbiota (functional dysbiosis), 308
  19.7 Functional composition of microbiota in IBD, 308
  19.8 Challenges, 310
  19.9 Conclusion, 310
  Take-home message, 310
  References, 310

20 Ankylosing spondylitis, klebsiella and the low-starch diet, 317
  Alan Ebringer, Taha Rashid and Clyde Wilson
  20.1 Introduction, 317
  20.2 Clinical features of AS, 317
  20.3 Gut bacteria and total serum IgA, 318
  20.4 Molecular mimicry in AS, 319
  20.5 Pullulanase system and collagens, 320
  20.6 Specific antibodies to Klebsiella in AS patients, 321
  20.7 The low-starch diet in AS, 322
  20.8 Conclusions, 324
  Take-home message, 325
  References, 325

21 Microbiome of chronic plaque psoriasis, 327
  Lionel Fry
  21.1 Introduction, 327
  21.2 Microbiota in psoriasis, 329
    21.2.1 Bacteria, 329
    21.2.2 Fungi, 330
  21.3 Variation of microbiota with site, 331
  21.4 Swabs versus biopsies, 331
  21.5 Psoriatic arthritis, 331
21.6 Microbiome and immunity, 332
21.7 Evidence that the skin microbiome may be involved in the pathogenesis of psoriasis, 332
  21.7.1 Psoriasis and Crohn’s disease, 332
  21.7.2 Genetic factors, 333
  21.7.3 Innate immunity, 333
21.8 New hypothesis on the pathogenesis of psoriasis, 334
Take-home message, 334
References, 335

22 Liver disease: interactions with the intestinal microbiota, 339
  Katharina Brandl and Bernd Schnabl
  22.1 Introduction, 339
  22.2 Non-alcoholic fatty liver disease, 339
  22.3 Qualitative and quantitative changes in the intestinal microbiota, 340
  22.4 Endotoxin, 341
  22.5 Ethanol, 342
  22.6 Choline, 342
  22.7 Alcoholic liver disease, 343
    22.7.1 Qualitative and quantitative changes in the intestinal microbiome, 343
    22.7.2 Contribution of dysbiosis to alcoholic liver disease, 344
  Take-home message, 346
  References, 346

23 The gut microbiota: a predisposing factor in obesity, diabetes and atherosclerosis, 351
  Frida Fåk
  23.1 Introduction, 351
  23.2 The “obesogenic” microbiota: evidence from animal models, 351
  23.3 The “obesogenic” microbiota in humans, 352
  23.4 A leaky gut contributing to inflammation and adiposity, 352
  23.5 Obesity-proneness: mediated by the gut microbiota?, 353
  23.6 Bacterial metabolites provide a link between bacteria and host metabolism, 353
  23.7 Fecal microbiota transplants: can we change our gut bacterial profiles?, 354
  23.8 What happens with the gut microbiota during weight loss?, 354
  23.9 The “diabetic” microbiota, 355
    23.9.1 Type I diabetes and the gut microbiota, 355
    23.9.2 Type II diabetes, 355
  23.10 The “atherosclerotic” microbiota, 356
  23.11 Conclusions, 357
  Take-home message, 357
  References, 357

24 The microbiota and susceptibility to asthma, 361
  Olawale Salami and Benjamin J. Marsland
  24.1 Introduction, 361
  24.2 The microenvironment of the lower airways, 361
24.3 Development of the airway microbiota in the neonate, 362
  24.3.1 Intrauterine microbial exposure and airway microbiota, 362
  24.3.2 Perinatal events and airway microbiota, 363
  24.3.3 Breast milk as a source of airway microbiota, 364
  24.3.4 Airborne microbiota and airway microbiota, 364
24.4 Upper airway microbiota, 364
24.5 What constitutes a healthy airway microbiota, 365
24.6 Microbiota and asthma, 365
24.7 Dietary metabolites and asthma, 366
24.8 Conclusion, future perspectives and clinical implications, 367
Take-home message, 367
References, 367

25 Microbiome and cancer, 371
  Ralph Francescone and Débora B. Vendramini-Costa
25.1 Introduction, 371
25.2 Microbiome and cancer: where is the link?, 374
25.3 Microbiome and barrier disruption, 376
25.4 Microbiome and different types of cancer, 377
  25.4.1 Colon cancer, 377
  25.4.2 Skin cancer, 378
  25.4.3 Breast cancer, 379
  25.4.4 Liver cancer, 379
  25.4.5 Local microbes affecting distant cancers, 381
25.5 Microbiota and metabolism: the good and the bad sides, 382
25.6 Chemotherapy, the microbiome and the immune system, 384
25.7 Therapeutic avenues, 385
  25.7.1 Modulation of bacterial enzyme activity, 385
  25.7.2 Antibiotics, 386
  25.7.3 Pre- and probiotics, 386
  25.7.4 Fecal transplantation, 386
25.8 Unresolved questions and future work, 387
Take-home message, 387
References, 387

26 Colorectal cancer and the microbiota, 391
  Iradj Sobhani and Séverine Couffin
26.1 Introduction, 391
26.2 Colon carcinogenesis and epidemiological data, 392
  26.2.1 Human carcinogenesis model, 392
  26.2.2 Age-related risk in the general population, 393
  26.2.3 Gene- and familial-related risks, 393
  26.2.4 Environment-related risk, 394
26.3 The microbiota, 394
26.4 Bacteria and CRCs links, 395
  26.4.1 Historical data, 395
  26.4.2 Clinical data, 396
  26.4.3 Experimental data and mechanisms involved, 397
Contents

26.5 Hypotheses and perspectives, 402
Take-home message, 405
References, 405

27 The gut microbiota and the CNS: an old story with a new beginning, 409
Aadil Bharwani and Paul Forsythe
27.1 Introduction, 409
27.2 The microbiota-gut-brain axis: a historical framework, 410
27.3 The microbiota-gut-brain axis: an evolutionary perspective, 411
27.4 The gut microbiota influence on brain and behavior, 413
27.5 Microbes and the hardwired gut brain axis, 415
  27.5.1 The vagus, 416
  27.5.2 The enteric nervous system, 417
27.6 Hormonal pathways to the brain, 418
27.7 Microbes and immune pathways to the brain, 420
27.8 Metabolites of the microbiota: short-chain fatty acids, 421
27.9 Clinical implications of the microbiota-gut-brain axis, 422
27.10 Conclusion, 422
Take-home message, 423
References, 423

28 Genetic dysbiosis: how host genetic variants may affect microbial biofilms, 431
Luigi Nibali
28.1 The holobiont: humans as supra-organisms, 431
28.2 Genetic variants in the host response to microbes, 432
  28.2.1 Bacterial recognition pathway, 432
  28.2.2 Bacterial proliferation, 433
28.3 Genetic dysbiosis, 434
  28.3.1 Genetic dysbiosis of oral biofilm, 435
  28.3.2 Genetic dysbiosis of gut biofilm, 435
  28.3.3 Genetic dysbiosis of skin biofilm, 436
  28.3.4 Genetic dysbiosis of vaginal biofilm, 437
28.4 Summary and conclusions, 438
Take-home message, 438
References, 438

Section 5 Mirroring the future: dysbiosis therapy, 443

29 Diet and dysbiosis, 445
Mehrbod Estaki, Candice Quin and Deanna L. Gibson
29.1 Introduction, 445
29.2 Coevolution of the host-microbiota super-organism, 445
29.3 Gut microbiota in personalized diets, 446
29.4 The evolution of diet, 447
29.5 Plasticity of the microbiota and diet, 447
29.6 Interaction among gut microbiota, host and food, 448
29.7 Consequences of diet-induced dysbiosis for host health, 450
29.8 The role of gut microbes on the digestion of macronutrients, 451
  29.8.1 Carbohydrates, 451
  29.8.2 Proteins, 451
  29.8.3 Lipids, 452
29.9 Diet induces dysbiosis in the host, 452
  29.9.1 Protein, 453
  29.9.2 Carbohydrates, 453
  29.9.3 Lipids, 454
29.10 The effect of maternal diet on offspring microbiota, 456
29.11 The effects of post-natal diet on the developing microbiota of neonates, 457
  29.11.1 Breast milk, 457
  29.11.2 Formula, 458
29.12 Conclusion, 459
Take-home message, 459
Host-food, 460
References, 460

30 Probiotics and prebiotics: what are they and what can they do for us?, 467
Marie-José Butel, Anne-Judith Waligora-Dupriet
30.1 The gut microbiota, a partnership with the host, 467
30.2 Probiotics, 467
  30.2.1 Probiotics, a story that began a long time ago, 467
  30.2.2 What are probiotics?, 468
  30.2.3 How do probiotics work?, 468
  30.2.4 Safety of probiotics, 469
30.3 Prebiotics, 470
  30.3.1 What are prebiotics?, 470
  30.3.2 How do prebiotics work?, 471
30.4 Synbiotics, 471
30.5 Pro-, pre-, and synbiotics in human medicine today, 471
  30.5.1 Pro- and prebiotics and infectious diarrhea, 471
  30.5.2 Pro- and prebiotics and inflammatory bowel diseases, 472
  30.5.3 Pro- and prebiotics and irritable bowel syndrome, 473
  30.5.4 Pro- and prebiotics and allergy, 474
  30.5.5 Pro- and prebiotics and obesity and diabetes, 475
  30.5.6 Other indications, 475
  30.5.7 Pre- and probiotics in pediatrics, 476
30.6 Concluding remarks, 477
Take-home message, 478
References, 478

31 The microbiota as target for therapeutic intervention in pediatric intestinal diseases, 483
Andrea Lo Vecchio and Alfredo Guarino
31.1 Introduction, 483
31.2 Use of probiotics in pediatric intestinal diseases, 484
  31.2.1 Acute diarrhea, 484
  31.2.2 Inflammatory bowel diseases, 486